Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapy
Sidsel Pedersen, Rikke Boedker Holmstroem, Annika von Heymann, et al.
Acta Oncologica (2023) Vol. 62, Iss. 1, pp. 62-69
Open Access | Times Cited: 13

Showing 13 citing articles:

Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy
Mees Egeler, Julia Lai‐Kwon, Renaud Tissier, et al.
European Journal of Cancer (2024) Vol. 200, pp. 113601-113601
Closed Access | Times Cited: 6
Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma
Rikke Boedker Holmstroem, Sidsel Pedersen, Rebecca Jurlander, et al.
European Journal of Cancer (2024) Vol. 202, pp. 114023-114023
Open Access | Times Cited: 5
Real-World Impact of Low-Grade Toxicities to Adjuvant Pembrolizumab in Stage III Melanoma
Nasreen Abdul Aziz, David Burke, Sharanniyan Ragavan, et al.
JCO Oncology Practice (2025)
Closed Access
Neuropsychological and central neurologic effects of cancer immunotherapy: the start of a new challenge
Florence Joly, Hélène Castel, Annette Compter, et al.
Journal of Clinical and Experimental Neuropsychology (2025), pp. 1-20
Closed Access
Health indices for disease incidence risk and duration in the Semi-Markov setting
Antoine Soetewey, Catherine Legrand, Michel Denuit, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 2
Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel
Carolin Grote, Ann‐Sophie Bohne, Christine Blome, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 10
Open Access | Times Cited: 2
Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)
Katharina C. Kähler, Svea Hüning, D. Nashan, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 13, pp. 11705-11718
Open Access | Times Cited: 2
Longitudinal evaluation of health-related quality of life after removal of high-risk melanoma in a setting where adjuvant therapy is not available
Jovana Sladojevic, Jelena Dotlić, Tatjana Gazibara, et al.
Archives of Dermatological Research (2023) Vol. 316, Iss. 1
Closed Access | Times Cited: 1
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective
Katharina C. Kähler, Ralf Gutzmer, Yenny Angela, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 5
Open Access
Real-World Comparison of Health-Related Quality of Life Associated with Use of Immune-Checkpoint Inhibitors in Oncology Patients
Abdulrahman Alwhaibi, Miteb Alenazi, Saad D. Alnofaie, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4918-4918
Open Access
Adjuvant Immunotherapy in Older Patients with Stage III and Resected Stage IV Melanoma: Toxicity and Recurrence-Free Survival Outcomes from the Dutch Melanoma Treatment Registry
A. Özkan, Ellen Kapiteijn, Frederiek van den Bos, et al.
European Journal of Cancer (2024) Vol. 212, pp. 115056-115056
Open Access
Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project
Toni Maria Janke, Laura Moysig, Christine Blome, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 151, Iss. 1
Open Access
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma – Results of systematic literature research
Teresa Amaral, Lena Nanz, Lina María Serna-­Higuita, et al.
European Journal of Cancer (2024) Vol. 215, pp. 115160-115160
Open Access
Side effects, quality of life, and treatment adherence in melanoma patients undergoing systemic therapy
Ann‐Sophie Bohne, Katharina C. Kähler
Deleted Journal (2023) Vol. 29, Iss. 8, pp. 692-699
Closed Access
Page 1

Scroll to top